Tirzepatide long-term safety: separating the myths from the evidence

The myth: because tirzepatide is relatively new, we have no idea what happens long-term

This is the most persistent concern, and it deserves a straight answer. Tirzepatide is not an untested drug. The SURMOUNT clinical programme enrolled thousands of adults across multiple trials, with SURMOUNT-1 alone randomising 2,539 participants over 72 weeks, that is nearly a year and a half of closely observed, placebo-controlled data. The trial's safety findings were published in the New England Journal of Medicine and formed the evidence base for NICE's appraisal (TA1026, published December 2024). Separately, Eli Lilly ran the SURPASS diabetes programme across tens of thousands of patient-years of exposure before tirzepatide reached any weight-management licence.

What those trials found on safety was consistent: the side-effect profile was dominated by gastrointestinal events (nausea being the most reported) and serious adverse events were uncommon. No new, unexpected safety signal emerged that wasn't already on the radar from the wider GLP-1 class. That said, 72 weeks is not the same as a decade, and the honest position is that very long-run data (five-plus years) are still accumulating. Regulators know this, which is why the MHRA's Black Triangle scheme exists: it is an active mechanism for collecting post-marketing safety reports precisely so that any signal appearing after approval is detected quickly. You can review the NHS tirzepatide patient information page for a plain-English summary of what is currently known, or visit our dedicated tirzepatide safety page for a more detailed look at how the evidence has been assessed in a UK context.

The picture is not one of ignorance, it is one of structured, ongoing scrutiny. That distinction matters.

Side effects that do appear: how common, how serious, how long they last

The day-to-day side-effect pattern for tirzepatide is well-characterised. Gastrointestinal symptoms (nausea, loose stools, constipation, indigestion, burping) are the most frequently reported, and they cluster around the start of treatment and the weeks immediately following a dose increase. For most people they are manageable and fade as the body adjusts, often within a fortnight. Fatigue, headache and mild dizziness are also reported, particularly early on.

The more serious risks are less common but matter. Acute pancreatitis (severe, persistent stomach pain that may reach through to the back, with or without vomiting) is a known class-wide effect. In January 2026 the MHRA issued a formal Drug Safety Update reinforcing that anyone on a GLP-1 medicine who develops this symptom should stop treatment and seek urgent medical attention. Gallbladder problems, including gallstones and cholecystitis, are also flagged in the prescribing information; rapid weight loss of any cause can increase gallstone risk, which adds context. Kidney function can be affected indirectly if severe vomiting or diarrhoea leads to dehydration, staying hydrated is not optional guidance.

Injection-site reactions (redness, bruising, mild swelling) affect a minority of users and are reduced by rotating sites, abdomen, thigh and upper arm are all suitable. A broader overview of the side effects associated with Mounjaro covers the full spectrum, including rarer events listed in the Patient Information Leaflet.

When to get medical help, and how to report what you experience

Most people using tirzepatide never need urgent medical input. A few situations should prompt you to contact a doctor or, where symptoms are severe, call 111 or 999. These include: severe stomach pain, especially pain that radiates to the back; signs of an allergic reaction (swelling of the face, throat, difficulty breathing, rash); persistent vomiting or diarrhoea that is stopping you from keeping fluids down; symptoms that could suggest gallbladder problems (pain in the upper right abdomen, fever, yellowing of the skin or eyes); and any significant change in mood, including thoughts of self-harm.

If you notice something unexpected on treatment, you can report it directly to the MHRA using the Yellow Card scheme. Patients can report as well as healthcare professionals, and given that tirzepatide is still under enhanced surveillance, patient reports genuinely contribute to the safety picture. You can also flag concerns to our clinical aftercare team, who are available seven days a week.

Understanding which symptoms need action is part of what our prescribers discuss during consultation, it is not an afterthought.

What happens to the safety evidence as you continue treatment

One question our prescribers hear regularly is whether risks compound over time, does staying on tirzepatide for a second or third year add layers of danger? Based on current evidence, that does not appear to be the case. The adverse event rates seen in SURMOUNT-1 did not increase progressively over the 72-week period; if anything, GI tolerability improved as participants settled into their maintenance dose. Longer-term extensions and real-world registry data are being gathered across the EU and UK under post-authorisation commitments, and the MHRA's enhanced monitoring means any shift in the safety signal will be visible quickly.

What does matter over time is regular clinical review. Weight, blood pressure, any new medicines you've started, and your own experience of treatment should all be assessed before each repeat. That review is also the moment to consider whether continuing is still the right choice, for some people, treatment will have served its purpose; for others, long-term use is appropriate and evidence-supported. You can read more about how the long-term safety picture for Mounjaro continues to develop, or explore the specific long-term side effects researchers are watching in tirzepatide's extended follow-up data. A fuller look at the clinical landscape is also available on our Mounjaro safety overview.

If you're thinking about starting treatment and want to discuss your own history with a prescriber, check your eligibility and begin a free consultation, our prescribers cover safety and suitability in detail before any prescription is considered.